Last $43.90 USD
Change Today -0.14 / -0.32%
Volume 222.6K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:37 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 8000

Fax:

very and fulfillment services. VIVITROL is sold directly to pharmaceutical wholesalers, specialty pharmacies and a specialty distributor. The company sells its product VIVITROL to McKesson Corporation, CVS Caremark Corporation, and AmerisourceBergen Drug Corporation. Patents and Proprietary Rights The company owns approximately 200 issued U.S. patents. Its oral controlled release technology is protected by a patent estate including patents and patent applications filed worldwide. The latest of the patents covering AMPYRA/FAMPYRA, which incorporates the company’s oral controlled release technology, expires in 2027 in the U.S. and 2025 in Europe. The company’s NanoCrystal technology patent portfolio contains various patents granted throughout the world, including the U.S. and countries outside of the U.S. It also has a significant various pending patent applications covering its NanoCrystal technology. The latest of the patents covering INVEGA SUSTENNA expires in 2019 in the U.S. and 2022 in the EU. The company has filed patent applications worldwide that cover its microsphere technology and have a significant number of patents and pending patent applications covering its microsphere technology. The company’s patents covering VIVITROL, RISPERDAL CONSTA and BYDUREON expire in 2029, 2023 and 2025 in the U.S., respectively, and 2021, 2021 and 2024 in Europe, respectively. The company also has patent protection for its key development programs. U.S. Patent No. 8,431,576, which issued in April 2013, covers a class of compounds that includes aripiprazole lauroxil and expires in 2030. U.S. Patent No. 7,262,298, which covers a class of compounds that includes the opioid modulators in each of the ALKS 5461 and ALKS 3831 combination products, expires in 2025. The company’s trademarks, including VIVITROL, are major to it and are generally covered by trademark applications or registrations in the U.S. Patent and Trademark Office and the patent or trademark offices of other countries. Its partnered products also use trademarks that are owned by its partners, such as the marks RISPERDAL CONSTA and INVEGA SUSTENNA, which are registered trademarks of Johnson & Johnson Corp., BYDUREON, which is a trademark of Amylin Pharmaceuticals, LLC, and AMPYRA and FAMPYRA, which are registered trademarks of Acorda. Competition In the treatment of alcohol dependence, VIVITROL competes with CAMPRAL (acamprosate calcium) sold by Forest Laboratories and ANTABUSE sold by Odyssey Pharmaceuticals (Odyssey), as well as marketed drugs also formulated from naltrexone. In the treatment of opioid dependence, VIVITROL competes with methadone, oral naltrexone, and SUBOXONE (buprenorphine HCl/naloxone HCl dehydrate sublingual tablets), SUBOXONE (buprenorphine/naloxone) Sublingual Film, and SUBUTEX (buprenorphine HCl sublingual tablets), each of which is marketed and sold by Reckitt Benckiser Pharmaceuticals, Inc. in the U.S. BYDUREON competes with other glucagon-like peptide-1 (GLP-1) agonists, including VICTOZA (liraglutide (rDNA origin) injection), which is marketed and sold by Novo Nordisk A/S. Trademarks CODAS, IPDAS, LinkeRx, MXDAS, NanoCrystal, SODAS, VERELAN and VIVITROL are registered trademarks of the company. Regulatory The company makes its products available for purchase by authorized users of the Federal Supply Schedule (FSS) of the General Services Administration pursuant to its FSS contract with the Department of Veterans Affairs. Under the Veterans Health Care Act of 1992 (the VHC Act), it is required to offer deeply discounted FSS contract pricing to four federal agencies: the Department of Veterans Affairs; the Department of Defense; the Coast Guard; and the Public Health Services (including the Indian Health Service)—for federal funding to be made available for reimbursement of any of its products by such federal agencies and certain federal grantees. The company is subject to the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. corporations and their representatives from paying, offering to pay, promising, authorizing, or making payments of anything of value to any foreign government officia

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $43.90 USD -0.14

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $70.33 USD +1.23
Cosmo Pharmaceuticals SpA SFr.181.00 CHF +2.50
Impax Laboratories Inc $24.37 USD -0.11
Jazz Pharmaceuticals PLC $158.78 USD +1.91
Pacira Pharmaceuticals Inc/DE $104.75 USD -0.78
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 4.7x
Price/Cash Flow 132.6x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.